Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? | Zendy

Fabrizio CarnevaleSchianca | Zendy; Susanna Gallo | Zendy; Delia RotaScalabrini | Zendy; Dario Sangiolo | Zendy; Marco Fizzotti | Zendy; Daniela Caravelli | Zendy; Antonio Capaldi | Zendy; Giancarlo Anselmetti | Zendy; Erica Palesandro | Zendy; Lorenzo D’Ambrosio | Zendy; Valentina Coha | Zendy; R Obert | Zendy; Massimo Aglietta | Zendy; Giovanni Grignani | Zendy

Open Access

Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?

Author(s) -

Fabrizio CarnevaleSchianca,

Susanna Gallo,

Delia RotaScalabrini,

Dario Sangiolo,

Marco Fizzotti,

Daniela Caravelli,

Antonio Capaldi,

Giancarlo Anselmetti,

Erica Palesandro,

Lorenzo D’Ambrosio,

Valentina Coha,

R Obert,

Massimo Aglietta,

Giovanni Grignani

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.35.6733

Subject(s) - medicine , bleomycin , imatinib mesylate , pneumonitis , chemotherapy , toxicity , lymphoma , oncology , imatinib , lung , myeloid leukemia

Bleomycin-induced pneumonitis (BIP) is a scarcely manageable pulmonary toxicity that occurs in approximately 20% of patients who are affected with cancers that are treated with bleomycin-containing regimens. Generally, the clinical picture is extremely complicated and therapy is based on steroids. The overall response rate to such therapy is limited. Recent insights in BIP pathogenesis have indicated that a key feature is deregulated mechanisms of tissue repair that are driven by profibrotic cytokines. Here we describe a patient with lifethreatening BIP who was completely cured with imatinib mesylate (IM) after steroids and all other therapies had failed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research